To evaluate the safety, tolerability and the amount of MK-6482 in your blood when given as tablets with different amounts of the crystalline form of the drug. MK-6482 is intended to treat renal cell carcinoma

3 x 5 nights
1 visits

During Study 2035, participants will receive the investigative treatment via an oral dose pill of MK-6482.

There is one screening appointment before the overnight stay, and a COVID swab test. There is one follow-up visit required. Compensation for study participation will be provided for time and travel of up to $5,075.

This study has been approved by an independent ethics committee.

Call Lindsay at 651-368-3360 or email her at lindsayd@nucleusnetwork.com to discuss your eligibility today!

Eligibility

Biological Sex Healthy males or females
Contraception Requirements Men must have had a vasectomy, women must be of non-childbearing potential
Age 18 - 65 years old
BMI 18 -32
Weight >110 llbs
Medications Able to avoid taking any medications 2 weeks prior to first drug administration
Smoking History Non-smoker/non-vaper